Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [7] - For the full year, revenue reached $376.6 million, a growth of 20% over fiscal 2024 [7][23] - Gross margin for Q4 was 51.3%, and for the full year, it was 50.7%, an increase from 42.6% in fiscal 2024 [7][23] - Adjusted EBITDA loss improved to approximately $7.8 million for Q4 and $46.9 million for the full year, showing significant improvement compared to fiscal 2024 [27][28] Business Line Data and Key Metrics Changes - SynBio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million, also a 17% growth [8][23] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, and for the full year, it reached $208.1 million, a growth of 23% [12][24] - Biopharma revenue was $6.4 million for Q4, a 22% increase year-over-year, with full-year revenue at $23.5 million, a growth of 15% [14][24] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [25] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth [25] - China accounted for approximately 1% of total revenue for fiscal 2025, indicating a relatively small market share [25] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven by the end of fiscal 2026, focusing on setting the stage for future growth acceleration [8] - A new product introduction for NGS aimed at minimal residual disease (MRD) is expected to launch commercially in early 2026, enhancing the company's offerings in cancer diagnostics [18][21] - The company plans to combine SynBio and Biopharma revenue reporting under the term DNA Synthesis and Protein Solutions to better reflect its customer base and operational synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in AI-enabled drug discovery, with significant orders from customers in this area [10][29] - The company anticipates total revenues of $425 million to $435 million for fiscal 2026, reflecting a growth of approximately 13% to 15.5% year-over-year [29] - Management emphasized the importance of staying close to customers to anticipate emerging needs and drive product innovation [32] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [28] - Capital expenditures for fiscal 2025 were $28 million, reflecting investments in growth for the upcoming fiscal year [28] Q&A Session Summary Question: On gross margins and pricing - Management indicated that gross margin expectations are influenced by customer mix and that they expect to maintain a strong margin trajectory moving forward [36][37] Question: NGS growth expectations - Management clarified that NGS growth is expected to rebound to 20% by Q4 2026, with a significant customer ramp anticipated [39][40] Question: Biopharma order sustainability - Management expressed optimism about the sustainability of AI-driven orders and the close ties between Biopharma and SynBio offerings [41][42] Question: Guidance for gross margins - Management expects gross margins to improve throughout fiscal 2026, driven by revenue growth and continuous process improvements [44][45] Question: Market opportunity definition - Management acknowledged the need for clearer market opportunity definitions and metrics to help investors understand growth potential [60][63]

Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [7] - For the full fiscal year 2025, revenue reached $376.6 million, a growth of 20% compared to fiscal 2024 [7][23] - Gross margin for Q4 was 51.3%, and for the full year, it was 50.7%, an increase from 42.6% in fiscal 2024 [7][23] Business Line Data and Key Metrics Changes - Synbio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million from $123.5 million in fiscal 2024 [8][23] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, with full-year revenue at $208.1 million, reflecting a 23% growth [12][24] - Biopharma revenue for Q4 was $6.4 million, a 22% increase year-over-year, with full-year revenue at $23.5 million, a 15% growth [14][24] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [25] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth [25] Company Strategy and Development Direction - The company plans to combine Synbio and Biopharma revenue reporting under the term "DNA synthesis and protein solutions" to better reflect its customer base [16] - A focus on AI-driven drug discovery is expected to drive future growth, with significant orders from customers in this area [10][29] - The introduction of the MRD Express product is aimed at enhancing cancer diagnostics and treatment, with a commercial launch expected in early 2026 [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth opportunities, particularly in AI-enabled drug discovery and the integration of Synbio and Biopharma services [10][32] - The company anticipates total revenues for fiscal 2026 to be between $425 million and $435 million, reflecting a growth of approximately 13% to 15.5% year-over-year [29] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [28] - Adjusted EBITDA for Q4 was a loss of approximately $7.8 million, an improvement of $9.2 million compared to Q4 of fiscal 2024 [27] Q&A Session Summary Question: On gross margins and pricing - Management indicated that while they expect to maintain strong gross margins, specific customer mix may influence quarterly results [36][37] Question: NGS growth expectations - Management expects NGS growth to return to 20% by Q4, driven by customer transitions and new product introductions [38] Question: Sustainability of AI-driven biopharma orders - Management remains optimistic about the biopharma business, highlighting the close ties to Synbio offerings and the potential of AI [40][41] Question: Guidance for gross margins and NGS portfolio - Management anticipates improvements in gross margins throughout the year, driven by revenue growth and continuous process improvements [43][44] Question: Market opportunity definition - Management acknowledged the need for clearer market definitions and metrics to help investors understand growth potential [59][62]

Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4 2025, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [5][21] - For the full fiscal year 2025, total revenue reached $376.6 million, a growth of 20% compared to fiscal 2024 [5][21] - Gross margin for Q4 was 51.3%, while the full-year gross margin was 50.7%, an increase from 42.6% in fiscal 2024 [5][21] Business Line Data and Key Metrics Changes - Synbio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million from $123.5 million in fiscal 2024 [6][21] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, with full-year revenue reaching $208.1 million, a growth of 23% [10][22] - Biopharma revenue was $6.4 million for Q4, reflecting a 22% increase year-over-year, with full-year revenue at $23.5 million, a growth of 15% [12][22] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [23] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth, with China accounting for approximately 1% of total revenue for fiscal 2025 [23] Company Strategy and Development Direction - The company plans to combine Synbio and Biopharma revenue reporting under the term "DNA synthesis and protein solutions" to better reflect its customer base and operational synergies [14] - A focus on AI-driven drug discovery is expected to drive future growth, with significant orders from customers in this area [8][22] - The introduction of the MRD Express product is aimed at enhancing cancer diagnostics and treatment, with a planned commercial launch in early 2026 [16][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, expecting total revenues for fiscal 2026 to be between $425 million and $435 million, reflecting a year-over-year growth of approximately 13% to 15.5% [27] - The company anticipates achieving adjusted EBITDA breakeven by the end of fiscal 2026, with gross margins expected to remain above 52% [28][29] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [25] - Adjusted EBITDA for Q4 was a loss of approximately $7.8 million, an improvement of $9.2 million compared to Q4 of fiscal 2024 [24] Q&A Session Summary Question: On gross margins and pricing dynamics - Management noted that while they expect to maintain strong gross margins, specific customer mix and tough comparisons from previous quarters may impact short-term results [33][34] Question: Guidance for NGS growth - Management clarified that the NGS guidance reflects a temporary air pocket due to customer transitions, with expectations of returning to 20% growth by Q4 2026 [35][36] Question: Insights on Synbio and biopharma orders - Management highlighted the strategic importance of biopharma and the positive momentum driven by AI, indicating strong future growth potential [37] Question: Market opportunity and revenue per assay - Management acknowledged the need for clearer metrics on market size and penetration, indicating that they are working on providing better insights for investors [55][58]

Fiscal 2025 4Q and Full Year Financial Results N O V E M B E R 2 0 2 5 Agenda Welcome Angela Bitting SVP, Corporate Affairs Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session 2 | TWIST BIOSCIENCE | PROPRIETARY Legal Disclaimers This presentation contains forward-looking statements. All statemen ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Revenue Growth - Record revenue of $376.6 million in Fiscal 2025, an increase of 20% from $313.0 million in Fiscal 2024[1] - Q4FY25 revenue reached $99.0 million, up 17% from $84.7 million in Q4FY24, marking the 11th consecutive quarter of sequential growth[1] - SynBio revenue grew 17% to $145.0 million in FY25 compared to $123.5 million in FY24[3] - NGS revenue increased by 23% to $208.1 million in FY25 from $169.1 million in FY24[3] - Biopharma revenue rose 15% to $23.5 million in FY25 compared to $20.3 million in FY24[3] - For FY26, total revenue is expected to be between $425 million and $435 million, representing a growth of 13% to 15.5% year-over-year[10] - Revenues for the three months ended September 30, 2025, increased to $99,009,000, up 16.9% from $84,710,000 in 2024[22] Profitability and Margins - Gross margin improved to 50.7% in FY25, an increase of 8.1 percentage points from 42.6% in FY24[1] - Gross margin for FY26 is projected to be above 52%[10] - Adjusted EBITDA for FY25 was $(46.9) million, an improvement from $(93.5) million in FY24[5] - Adjusted EBITDA for the three months ended September 30, 2025, was $(7,848,000), an improvement from $(17,042,000) in 2024[26] Expenses and Losses - Net loss attributable to common stockholders for the three months ended September 30, 2025, was $27,138,000, compared to a loss of $34,655,000 in 2024, representing a 21.5% improvement[22] - Research and development expenses for the three months ended September 30, 2025, were $17,014,000, down 19.5% from $21,134,000 in 2024[22] - Selling, general and administrative expenses increased to $63,758,000 for the three months ended September 30, 2025, up 19.9% from $53,143,000 in 2024[22] Assets and Liabilities - Total current assets decreased to $332,966,000 as of September 30, 2025, from $346,776,000 in 2024, a decline of 4.0%[24] - Total liabilities increased to $168,903,000 as of September 30, 2025, compared to $141,634,000 in 2024, an increase of 19.2%[24] - Cash and cash equivalents decreased to $183,049,000 as of September 30, 2025, down from $226,316,000 in 2024, a decrease of 19.1%[24] Other Financial Highlights - The company shipped approximately 938,000 genes in FY25, up from approximately 772,000 in FY24[9] - The company reported a gain on the sale of business amounting to $48,847,000 for the twelve months ended September 30, 2025[22] - The weighted average shares used in computing net loss per share attributable to common stockholders increased to 60,424,000 in 2025 from 58,554,000 in 2024[22]

Core Insights - Twist Bioscience Corporation announced its financial results for the fourth quarter and full year of fiscal 2025, ending September 30, 2025 [1] Financial Results - The company will issue its financial results before the market opens on November 14, 2025, and will hold a conference call at 8:00 a.m. Eastern Time to discuss these results [10] Business Highlights - Twist Bioscience focuses on providing synthetic DNA tools for various fields including medicine, agriculture, industrial chemicals, and defense, aiming to improve lives and sustainability [4] - The company utilizes an innovative silicon-based DNA Synthesis Platform that offers precision and efficiency in synthesis, sequencing, and therapeutics discovery [5] Upcoming Events - Emily M. Leproust, Ph.D., CEO, and Adam Laponis, CFO, will participate in a fireside chat at the 7th Annual Wolfe Research Healthcare Conference on November 17, 2025 [8]

Core Insights - Twist Bioscience Corporation is set to release its fourth-quarter earnings on November 14, with analysts predicting a loss of 50 cents per share, an improvement from a loss of 59 cents per share in the same quarter last year [1] - The expected quarterly revenue for Twist Bioscience is $97.36 million, which represents an increase from $84.71 million year-over-year [1] - The company issued FY25 sales guidance that fell below market estimates on August 4 [1] Stock Performance - Shares of Twist Bioscience declined by 6.2%, closing at $29.90 on Thursday [2] Analyst Ratings - Stephens & Co. analyst Steven Etoch initiated coverage with an Overweight rating and a price target of $41 [6] - Goldman Sachs analyst Matthew Sykes maintained a Buy rating but reduced the price target from $55 to $48 [6] - Guggenheim analyst Subbu Nambi reiterated a Buy rating with a price target of $50 [6] - Baird analyst Catherine Ramsey maintained an Outperform rating and lowered the price target from $54 to $44 [6] - JP Morgan analyst Rachel Vatnsdal maintained an Underweight rating and cut the price target from $40 to $33 [6]

Core Viewpoint - Twist Bioscience Corporation is expected to report a quarterly loss of 50 cents per share, an improvement from a loss of 59 cents per share a year ago, with projected revenue of $97.36 million, up from $84.71 million last year [1] Financial Performance - The anticipated quarterly loss for Twist Bioscience is 50 cents per share, compared to a loss of 59 cents per share in the same quarter last year [1] - The consensus estimate for quarterly revenue is $97.36 million, reflecting a year-over-year increase from $84.71 million [1] Stock Performance - Shares of Twist Bioscience declined by 6.2%, closing at $29.90 [2] Analyst Ratings - Stephens & Co. initiated coverage with an Overweight rating and a price target of $41 [6] - Goldman Sachs maintained a Buy rating but reduced the price target from $55 to $48 [6] - Guggenheim reiterated a Buy rating with a price target of $50 [6] - Baird maintained an Outperform rating and lowered the price target from $54 to $44 [6] - JP Morgan maintained an Underweight rating and cut the price target from $40 to $33 [6]

Core Insights - Twist Bioscience Corporation (NASDAQ: TWST) stock has experienced double-digit gains this month, although it is trading at the lower end of its 52-week range [1] - The company is set to release its Q4 and FY2025 results within the next month, which could impact stock performance [1] Company Overview - Twist Bioscience is currently in a phase of stock price recovery, with recent performance indicating positive momentum [1] - The upcoming financial results are anticipated to provide insights into the company's operational performance and future outlook [1] Analyst Background - Gamu Dave Innocent Pasi, a financial professional with extensive experience in investment research, has been involved in analyzing financial statements and capital markets [1] - His expertise includes providing actionable trading ideas and investment recommendations, with a focus on promoting financial inclusion and sustainability [1]